Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

Jeffrey H. Lipton Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, CanadaCorrespondence[email protected]

Nina Khoroshko Department of Haematology, Haematology Research Center, Moscow, Russia

Anatoly Golenkov Department of Haematology, Moscow Regional Research Institute, Moscow, Russia

Kudrat Abdulkadyrov Department of Haematology, Institute of Haematology, St. Petersburg, Russia

Krishnan Nair Department of Oncology, Medical College Campus, Trivandrum, India

Digumarti Raghunadharao Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India

Tim Brummendorf Department of Hematology, Oncology and Immunology, University Medical Center II, Tubingen, Germany

Kisook Yoo Department of Biostatistics

Bengt Bergstrom On behalf of the pegasys CML study group Department of Medical Science, Hoffmann-La Roche, Inc., Nutley, NJ, USA

Your download is now in progress and you may close this window